What did Novo Nordisk’s September 11, 2026 announcement reveal about China’s approval of Wegovy (semaglutide) as the country’s first GLP 1 receptor agonist specifically indicated for metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to severe liver f

China’s approval gave injectable Wegovy a new, disease-specific use: treatment of adults with MASH and moderate-to-severe liver fibrosis, making it the country’s first GLP-1 receptor agonist approved for that indication. It is strategically important, but it does not by itself settle the investment case: uptake, reimbursement, pricing, and speed of liver-specialist adoption will determine whether it produces meaningful near-term sales. 24

• What China approved: Novo Nordisk said on September 11 that Wegovy (semaglutide) had become the first GLP-1 receptor agonist approved in China for MASH in adults with moderate-to-severe fibrosis. That moves the brand beyond chronic weight management and its established cardiovascular-risk-reduction positioning into a serious liver-disease treatment setting. 24

• International and formulation context: The China decision followed the UK’s July 2026 MASH approval. It is separate from China’s late-August action on oral Wegovy: the regulator accepted Novo’s marketing application for the once-daily semaglutide tablet for long-term weight management—it was an application acceptance, not an approval. 12

• Clinical significance: Jia Jidong of Beijing Friendship Hospital characterized the decision as a meaningful advance because MASH with fibrosis has a major unmet need and semaglutide offers an intervention addressing both liver disease and the underlying metabolic drivers. The available reporting supports that broad interpretation, although the exact wording of his full statement is not independently available in the retrieved sources. 5

• Analyst split: HSBC raised its Novo Nordisk target to DKK 320 from DKK 300 while retaining Hold, reflecting more confidence in the company’s longer-term pipeline/value potential. Barclays cut its target to DKK 300 from DKK 310 and kept Equal Weight/Neutral, signaling greater caution about nearer-term growth and execution. 146

• STEP Young: Novo reported positive Phase 3 results for once-weekly semaglutide plus lifestyle intervention in children aged 6 to under 12 with obesity. The headline outcome was that 40.4% achieved a BMI below the obesity threshold; the company said full results would be presented at a future scientific meeting. 133

• Buyback status at September 4: The overall program permits up to DKK 15 billion of B-share repurchases during the 12 months starting February 4, 2026. Its May 6 safe-harbour tranche authorizes up to about DKK 11.2 billion through February 1, 2027. By September 4, Novo had repurchased 32,034,179 B shares since February 4 at an average DKK 281.63, totaling about DKK 9.022 billion; 17,275,000 shares, worth about DKK 5.222 billion, were under the May tranche. 7812

• Why investors remain cautious: The positive MASH, pediatric, and capital-return developments arrive after roughly a 12% year-to-date share-price decline and against expectations for modest 2026 revenue and earnings contraction. The core pressures are obesity-drug pricing and competition, plus doubts about the breadth and timing of pipeline replacements for semaglutide-led growth.

• Pipeline risk: The halted HERMES and ATHENA Phase 3 ziltivekimab programs increase the importance of ARTEMIS, which remains ongoing. Novo’s prior investor material had listed all three as ongoing, so the subsequent stops reduce optionality in the inflammation/cardiovascular program. 16

The central question is therefore commercial rather than regulatory: whether the China MASH label promptly adds treated patients and reimbursed revenue, or remains a longer-dated franchise extension constrained by pricing, access, specialist adoption, and competition. Insufficient evidence is available yet to quantify incremental MASH sales.